ATNM Overview
Upcoming Projects (ATNM)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ATNM)
-
A second look: Discussing the commercial prospects of Iomab-B from Actinium Pharmaceuticals in Acute Myeloid Leukemia
Ticker: ATNM
Executed On: Nov 27, 2023 at 09:00 AM EST -
Discussing the commercial prospects of Iomab-B from Actinium Pharmaceuticals in Acute Myeloid Leukemia
Ticker: ATNM
Executed On: Nov 15, 2023 at 11:00 AM EST -
A look at the the potential of I apamistamab(Iomab-B) and it's P3 SIERRA Trial of Iomab-B in elderly patients with active relapsed or refractory AML
Ticker: ATNM
Executed On: Nov 14, 2022 at 08:00 AM EST
Upcoming & Overdue Catalysts (ATNM)
-
BLA submission Iomab-B
Ticker: ATNM
Future Window: Jan 01, 2024 - Jun 01, 2024
Overdue
Occurred Catalysts (ATNM)
-
Actinium (ATNM) Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial
Ticker: ATNM
Occurred on: Dec 29, 2020 -
Phase 3 presentation of Actinium Pharma's(ATNM) Iomab-B in Hematopoietic Stem Cells Transplantation expected at ASCO
Ticker: ATNM
Occurred on: Jun 04, 2019 -
Phase 3 data of Iomab-B in Hematopoietic Stem Cells Transplantation to be presented at TCT meeting February 24, 2019, 12:30pm CT.
Ticker: ATNM
Occurred on: Feb 25, 2019 -
Phase 3 trial read out for Iomab-B's Phase 3 trial in AML
Tickers: ATNM, CPXX
Occurred on: Aug 14, 2018 -
Actinium (ATNM) Initiates Phase 2 Trial Evaluating Actimab-A in Newly Diagnosed Acute Myeloid Leukemia Patients Over Age 60
Ticker: ATNM
Occurred on: Sep 27, 2016 -
Initiation of the Iomab-B's pivotal Phase 3 trial in AML refractory/relapsing patients
Tickers: ATNM, CPXX, MBRX
Occurred on: Jun 10, 2016
Strategic Initiatives (ATNM)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
